That said, this isn't a buy and bury situation. Mendeley is now very well positioned to dominate so there's no reason to worry, and anyways you can always take your data with you.
FYI - I work for Mendeley.
That said, this isn't a buy and bury situation. Mendeley is now very well positioned to dominate so there's no reason to worry, and anyways you can always take your data with you.
FYI - I work for Mendeley.
While I don't know the specific details of your agreement with Elsevier that make you so "well positioned to dominate," I do know that your target market's principles are more closely aligned with ours than with yours, and that they aren't stupid. You can't really preach open access for years and then sell yourself to the OA movement's greatest enemy and expect that no one will notice.
In any case, I welcome the competition, although I hope that in the future it comes in the form of shipped code and not more lies about the viability of free software.
FYI - I'm a member of the Zotero core team, but I'm also a graduate student in neuroscience at MIT.